Atomwise Stock

atomwise.comHealthcareFounded: 2012Funding to Date: $151.49MM

Atomwise is the developer of first deep learning technology designed for structure-based small molecule drug discovery.

Register for Details

For more details on financing and valuation for Atomwise, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Atomwise.

Register Today

Team

Management Team

Izhar Wallach Ph.D
Co-Founder & Chief Technology Officer
Han Lim
Vice President and Global Head of Partnering
Abraham Heifets Ph.D
Co-Founder & Chief Executive Officer

Board Members

Gavin Teo
B Capital Group
Adam Seabrook
B Capital Group
Kiersten Stead Ph.D
Monsanto Growth Ventures
Matthew Ocko
Data Collective

Other companies like Atomwise in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 

News

Atomwise, a company leveraging AI and machine learning to accelerate drug discovery, has raised $123 million in venture capital.
The folks behind Atomwise's spinout X-37 like to think in cosmological metaphors, and you can think of their AI drug development model as probes sent into space from a central station. That station just got $14.5 million in Series A funding from DCVC Bio, Alpha Intelligence Capital and Hemi Ventures